<DOC>
	<DOCNO>NCT02477787</DOCNO>
	<brief_summary>This single center , open label , random comparison phase 2b study . The primary objective study , random comparison , assess anti-leukemia effect allogeneic , donor-derived natural killer ( NK ) cell infuse HLA-haploidentical hematopoietic cell transplantation ( HCT ) patient refractory acute myelogenous leukemia ( AML ) . The secondary objective study assess side effect donor NK cell infusion , effect donor NK cell infusion upon HCT outcome , well effect upon post-HCT immune recovery .</brief_summary>
	<brief_title>Randomized Study Haploidentical Hct Subsequent Donor nk Cell Infusion High-risk AML MDS</brief_title>
	<detailed_description>5.0 Study design 5.1 . Study patient enrol PI Kyoo-Hyung Lee , MD Young-Shin Lee , RN . 5.2 . Random assignment 5.2.1 . Patients randomly assign study arm day initiation condition therapy ( day -8 ) . 5.2.2 . Stratification Refractory AML Stratification 1 : Primary refractory vs. relapse-refractory/2 relapse Stratification 2 : peripheral blood blast &lt; 5 % vs. ≥5 % 5.2.3. extra leukapheresis perform form donor assign treatment cohort . High-risk AML Stratification : AML CR1 high-risk feature vs. AML CR2 High-risk myelodysplastic syndrome ( MDS ) IPSS intermediate-2 risk vs. IPSS high-risk 6.0 . Patient Eligibility 6.1 . Patients refractory AML Refractory AML define follow ; 1 . Primary refractory : failure achieve complete remission ( CR ) 2 cycle induction chemotherapy ; , patient ≥65 year age , progressive AML treatment hypomethylating agent ( increase peripheral blood blast 50 % increase bone marrow blast 25 % ) 2 . Relapse refractory : recurrence AML , refractory standard salvage chemo therapy ; , patient ≥65 year age , hypomethylating agent 3 . AML ≥2 relapse 6.2 . Patients AML CR1 high-risk chromosomal feature complex abnormality ( 3 abnormality ) , -5 , 5q- , -7 , 7q- , 11q32 abn ( non ( 9 ; 11 ) ) , inv ( 3 ) , ( 3 ; 3 ) , ( 6 ; 9 ) , ( 9 ; 22 ) , monosomal karyotype 2 abnormalites Patients AML CR2 6.3 Patients MDS , intermediate-2 high risk category IPSS classification 6.4 . Patients 19 year age old 6.5 . Patients Karnofsky performance scale ≥70 6.6 . Patients cell donor must understand fully sign informed consent form Exclusion 6.7 . Pregnant lactate woman 6.8 . Patient abnormal liver function ( total bilirubin ≥ 5.0 mg/dl , AST ≥ 5 time upper normal limit ) 6.9 . Patients abnormal renal function ( creatinine ≥ 3.0 mg/dl ) 6.10 . Patients clinically-evident cardiac pulmonary dysfunction 6.11 . Patients infection progressive despite appropriate anti-microbial treatment 6.12 Patients hypersensitivity gentamicin 6.13 . Patients receive allogeneic cell therapy 7.0.Treatment Plan 7.1 . For study group patient , donor NK cell generate hematopoietic cell . Donor NK cell produce GCP laboratory Asan Institute Life Science team Stem Cell Research Center , Korea Research Institute Bioscience Biotechnology . 7.2 . Patients triple-lumen Hickman central-venous catheter ( CVC ) place . Chest X-ray take CVC placement confirm location absence hematoma formation pneumothorax . 7.3 . Lumbar puncture do preservative free methotrexate 10 mg/m2 ( exceed 15 mg total ) give intrathecally . 7.4 . Menstruating woman give norethindrone ( Norlutate ) 10 mg po daily . 7.5 . The preparative regimen ( Bu-Flu-ATG ; also see Appendix V ) : 7.5.1 . Busulfex ( Bu ) 3.2 mg/kg/day iv daily day -7 -6 . Patients older 64 year age significant co-morbidities may receive Bu day -7 . 7.5.2 . Fludarabine ( Flu ) 30 mg/m2/day D5W 100 ml iv 30 minute start 4 pm daily day -7 , -6 , -5 , -4 , -3 , -2 . 7.5.3 . Methylprednisolone 2 mg/kg D5W 100 ml iv 30 minute day -4 , -3 , -2 , -1 . 7.5.4 . Anti-thymocyte globulin ( Thymoglobulin , Genzyme Transplant , Cambridge , MA , USA ) 2.5 mg/kg/day N/S 500-800 ml ( le 4 mg/ml ) iv 4 hour start 8 daily day -3 , -2 , -1 . 7.6 . Hematopoietic stem cell collection donor . 7.6.1 . The HLA-haploidentical family donor receive granulocyte colony-stimulating factor ( G-CSF , Grasin ) 10 ug/kg subcutaneous ( sc ) injection 5 day ( day -3 day 1 ) . Daily CBC do . On day 0 , 1 , 2 , peripheral blood mononuclear cell collect leukapheresis ( Amicus , Fenwal ) . A female donor one poor peripheral vein may Quinton Groshong catheter place . A sample take cell count total cell , mononuclear cell , CD34+ cell , CD3+ cell , CD4+ cell , CD8+ cell . Cells collect day 0 1 , transplant patient day without manipulation . At least 2x106/kg CD34+ cell collect day 0 . If , additional collection may schedule discretion attend physician . G-CSF commonly administer agent donor cell-collection document long-term side effect document last 25 year ' use . However , cell donor study monitor possible side effect G-CSF . 7.6.2 . Cell collect collect day 2 transport GCP laboratory generation NK cell ( study arm ) . For detail donor NK cell generation , please see appendix V. 7.7 . Peripheral blood hematopoietic cell infusion transplantation ( day 0 0-1 0-2 ) . 7.7.1 . For ABO match minor mismatch transplantation , premedication Avil 45.5 mg iv push acetaminophen 600 mg po give . Stem cell infuse via CVC 1 hour . 7.7.2 For major ABO mismatch transplantation , premedication Avil 45.5 mg iv push , acetaminophen 600 mg po , 10 % mannitol 100 g iv 4 hour begin 30 minute stem cell infusion , hydrocortisone 250 mg iv immediately 30 minute stem cell infusion give . Stem cell infuse via CVC 1 hour . Donor NK cell infusion ( see appendix V ) 7.8 . The patient study arm receive donor NK cell infusion around day 13 20 . A permissible range infusion time +/- 3 day . 7.9 . For DNKI give day 13 ( DNKI-1 ) , cell dose 1-2 x108/kg half amount generate . For DNKI give day 20 ( DNKI-2 ) , cell dose 5x108/kg . 7.10 . Avil 1 ampoule give intravenously 30 minute prior NK cell infusion . 8.0 Supportive care . 8.1 . Dilantin 15 mg/kg ( ABW ) NS 200 ml iv 1 hour load day -8 , 200 mg po bid day -6 -5 . 8.2 . Clotrimazole powder groin , axilla , perianal area bid day -8 absolute neutrophil count ( ANC ) &gt; 3,000/ul . 8.3 . Sodium bicarbonate/saline mouthwash qid mucositis resolve . 8.4.. Micafungin 50 mg iv qd Day 1 ANC &gt; 3,000/ul . 8.5 . Ciprofloxacin 500 mg po bid ( selective bowel decontamination ) ANC &gt; 3,000/ul . With first fever spike , ciprofloxacin discontinue broad spectrum antibiotic begin . 8.6 . Acyclovir 250 mg/m2 iv twice day give day 1 , change acyclovir 400 mg po bid discontinuation cyclosporine administration . 8.7 . G-CSF 450ug iv daily day 5 ANC &gt; 3,000/ul . 8.8 . The patient hydrate 0.9 % NS 100 ml/hr patient receive busulfan . 8.9 . Azithromycin 125 mg iv po daily start ANC &gt; 500/ul 1 year evidence GVHD . In patient GVHD , azithromycin continue resolution GVHD discontinuation immunosuppressive therapy . 8.10 . Bactrim 2 po day three time week ANC &gt; 3,000/ul . 8.11 . Intravenous immunoglobulin 500 mg/kg ( ABW ) iv 6 hour every 2 week start day 7 day 90 monthly day 180 . 9 . GVHD prophylaxis 9.1 . Cyclosporine 1.5 mg/kg N/S 100 ml iv 2-4 hour q12 hrs begin day -1 . Adjust cyclosporine dose provide appropriate blood level ( 100-300 ng/ml whole blood ) accord change renal function . 9.2 . Cyclosporine dose changed oral dose oral feeding become feasible . Provided GVHD , cyclosporine dose taper 10 % -20 % every 2-4 week start day 30 60 HCT . 9.3 . Cytomegalovirus ( CMV ) Epstein-Barr virus ( EBV ) monitoring : Blood CMV antigenemia assay quantitative EBV PCR do least weekly start day -7 day 100 . If CMV antigenemia positive , preemptive treatment ganciclovir consider follow ; 5 mg/kg iv ( every 12 hour 7 day ) daily 1-2 week negative conversion CMV antigenemia . When EBV DNA detect PCR , infusion rituximab 375 mg/m2 consider weekly DNA longer detectable . 9.4 . CNS prophylaxis : Preservative-free methotrexate administer intrathecally patient recover platelet count 50,000/mcl . Methotrexate 10 mg/m2 ( exceed 15 mg total ) give intrathecally every 2 week three time ( total four dos include one give preparatory regimen ) . 10.0 . Treatment Evaluation 10.1 . Donor work include HLA-A , -B , -C , -DRB1 type base PCR-sequencing method , ABO/Rh typing , CBC reticulocyte count , chemistry , BUN/phosphorus , electrolytes , coagulation battery , urinalysis microscopy , EKG , chest PA lateral , HBsAg , HBsAb , HCV Ab , HIV Ab , VDRL , CMV ( IgG ) , HSV ( IgG ) , EBV serology , Toxoplasma titer ( IgG ) , VZV ( IgG ) ( Appendix II ) . 10.2 . Patient work include ; HLA-A , -B , -C , -DRB1 type base PCR-sequencing method , ABO/Rh typing , CBC reticulocyte count , chemistry , BUN/phosphorus , electrolytes , coagulation battery , urinalysis microscopy , MUGA scan echocardiogram , dental consult Panorex film , ENT consult PNS film , PFT DLCO , Chest X-ray , EKG , diagnostic lumbar puncture fluid battery ( cell count , glucose , protein , LD , fungal bacterial culture , cytospin ) , bone marrow aspirate biopsy cytogenetics appropriate molecular test ( bcr-abl , pml-rara , aml1-eto ) , HBsAg , HBsAb , HBcAb ( IgG ) , HCV Ab , HIV Ab , VDRL , CMV ( IgG , IgM ) , HSV ( IgG , IgM ) , EBV serology , Toxoplasma titer ( IgG ) , VZV ( IgG ) , serum pregnancy test ( beta-hCG ) female , isoagglutinin titer ABO mismatch HCT . 10.3 . The status mixed chimerism evaluate PCR analysis short tandem repeat ( STRs ) multiplex primer . The chimerism status analyze whole blood DNA 1 , 3 , 6 month HCT . 10.4 . Blood cytomegalovirus ( CMV ) antigenemia quantitative EBV PCR assay do least weekly day 100 HCT . 10.5 . Immune recovery patient stem cell transplantation monitor lymphocyte subset count ( Appendix VII ) measurement Ig G , Ig M , Ig A level Ig G subset ( G1 , G2 , G3 ) 1 , 3 , 6 , 12 month HCT . 10.6 . The patient follow physical examination appropriate blood test include CBC least every 3 month 3 year transplantation yearly thereafter . 10.7 . Bone marrow examination cytogenetics do 3 4 week HCT , subsequently , deem necessary . 10.8 . 5 ml bone marrow 15 ml heparinized blood obtain day -8 send Asan-KRIBB laboratory immune phenotyping functional analysis . In addition , 15 ml heparinized blood obtain 1 , 3 , 6 , 12 month HCT send Asan-KRIBB laboratory immune phenotyping functional analysis ( see Appendices VII VIII ) . 10.9.Plasma cytokine ( interferon-γ , TNF-α , IL-6 , IL-15 , soluble IL-2 receptor ) level measure 1 , 3 , 6 , 12 month HCT . 10.10 . On day DNKI ( day 13 20 ) , 5 ml heparinized peripheral blood send Asan-KRIBB laboratory ATG titer determination . 10.11 . 96 assessable patient enrol ( 48 DNKI arm ; 48 control arm ) . After enrollment 40 patient , interim analysis perform . 10.12 . The enrollment period 60 month approval Korean Ministry Food Drug Safety . 10.13 . Continuous variable compare use T-test Mann-Whitney test . Categorical variable compare use chi-square test . Lastly , time-event variable compare use log-rank test optional multivariate analysis necessary . 10.14 . Patients remove study immediately , patient withdraws consent participate study . 11.0 . Definition Endpoints Response 11.1.The occurrence severity side effect NK cell infusion observe study monitor graded accord Common Toxicity Criteria v3.0 ( 2006 ; National Cancer Institute ) . GVHD diagnose grade publish criterion list Appendix III . TRM define death occur transplantation without leukemia progression . 11.2.CR define blast le 5 % marrow recovery neutrophil count 1,000/ul extramedullary disease . CRmarrow define blast less 5 % marrow , blast peripheral blood , neutrophil count 500/ul , platelet count 20,000/ul , extramedullary disease . 11.3.Leukemia recurrence define 5 % leukemia blast bone marrow sample previously document CR . In patient persistent leukemia HCT , day leukemia progression define day leukemia blast reappear peripheral blood bone marrow examination show 5 % persistent blast . 11.4 . Event-free survival measure day HCT leukemia recurrence , transplantation-related mortality , last follow-up . Overall survival measure HCT death cause last follow-up .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<criteria>Patients refractory AML Refractory AML define follow ; 1 . Primary refractory : failure achieve complete remission ( CR ) 2 cycle induction chemotherapy ; , patient ≥65 year age , progressive AML treatment hypomethylating agent ( increase peripheral blood blast 50 % increase bone marrow blast 25 % ) 2 . Relapse refractory : recurrence AML , refractory standard salvage chemo therapy ; , patient ≥65 year age , hypomethylating agent 3 . AML ≥2 relapse Patients 19 year age old Patients Karnofsky performance scale ≥70 Patients cell donor must understand fully sign informed consent form Pregnant lactate woman Patient abnormal liver function ( total bilirubin ≥ 5.0 mg/dl , AST ≥ 5 time upper normal limit ) Patients abnormal renal function ( creatinine ≥ 3.0 mg/dl ) Patients clinicallyevident cardiac pulmonary dysfunction Patients infection progressive despite appropriate antimicrobial treatment Patients hypersensitivity gentamicin Patients receive allogeneic cell therapy previously .</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>HLA-haploidentical hematopoietic cell transplantation</keyword>
	<keyword>natural killer cell</keyword>
</DOC>